EAST HANOVER, N.J., April 11 /PRNewswire/ -- New data show that a once-yearly infusion of Reclast(R) (zoledronic acid) Injection 5mg was significantly better than risedronate at increasing bone mass ...

The U.S. Food and Drug Administration (FDA) has approved Reclast® (zoledronic acid) Injection, the first and only once-yearly treatment for postmenopausal osteoporosis. Approximately 8 million women ...

Single infusion of Reclast increases bone mass for two years in postmenopausal women with osteopenia, a condition that can lead to osteoporosis[1] Approximately 22 million women in US have osteopenia, ...

DEAR DR. ROACH: For the last few years, I have been taking yearly Reclast infusions for osteoporosis, because I have trouble taking oral medications of any kind. The infusion was given in February ...

Reclast (zoledronic acid or zoledronate) is approved by the Food and Drug Administration (FDA) to treat and prevent osteoporosis in males, females after menopause, and people taking glucocorticoids.

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: For the last few years, I have been taking yearly Reclast ...

DEAR DR. ROACH: For the last few years, I have been taking yearly Reclast infusions for osteoporosis, because I have trouble taking oral medications of any kind. The infusion was given in February ...

June 4, 2009 — The FDA this month has approved zoledronic acid infusion (Reclast, Novartis Pharmaceuticals Corp) for the prevention of postmenopausal osteoporosis during a 2-year period. "It is very ...

The FDA has approved Reclast (zoledronic acid injection, from Novartis) for the prevention of new clinical fractures in patients who have recently had a low-trauma hip fracture. The approval was based ...

*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Dear Dr. Roach: For the last few years, I have been taking yearly Reclast infusions for osteoporosis, because I have trouble ...

Reclast is also indicated to increase bone mass in men with osteoporosis; for the treatment of Paget's disease of bone (men and women); and for the treatment and prevention of glucocorticoid-induced ...

* Announced u.s. Launch of zoledronic acid injection, 5 mg/100 ml single dose vial, a generic version of novartis' reclast® injection * Mylan NV - received final approval from u.s. Fda for its ...